GSA Capital Partners’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

GSA Capital Partners’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,201	Closed	-$413K	–	1318
2020 Q1	$413K	Buy	+15,201	New	+$423K	0.1%	271
2018 Q1	–	Sell	-113,294	Closed	-$1.58M	–	1923
2017 Q4	$1.58M	Buy	113,294 +55,594	+96%	+$751K	0.1%	329
2017 Q3	$1.07M	Buy	+57,700	New	+$965K	0.07%	485
2016 Q1	–	Sell	-88,251	Closed	-$1.31M	–	2018
2015 Q4	$1.31M	Buy	88,251 +66,130	+299%	+$1.11M	0.06%	502
2015 Q3	$363K	Sell	22,121 -22,428	-50%	-$459K	0.02%	1272
2015 Q2	$1.02M	Buy	+44,549	New	+$887K	0.04%	885
2014 Q2	–	Sell	-18,114	Closed	-$211K	–	2023
2014 Q1	$211K	Sell	18,114 -5,400	-23%	-$91.4K	0.02%	1355
2013 Q4	$416K	Buy	23,514 +606	+3%	+$10.2K	0.03%	975
2013 Q3	$330K	Buy	22,908 +3,015	+15%	+$46.1K	0.03%	1078
2013 Q2	$300K	Buy	+19,893	New	+$263K	0.04%	868

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GSA Capital Partners's MNTA Position: Q2 2020 in Review

GSA Capital Partners sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2020, closing a stake of 15,201 shares — an estimated $413K sold.

GSA Capital Partners first reported a position in MNTA in Q2 2013 and held it in 10 quarters. The position peaked at $1.58M in Q4 2017. 237 funds tracked by Wall St. Rank hold MNTA as of Q2 2020.

GSA Capital Partners reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
GSA Capital Partners sold 15,201 Momenta Pharmaceuticals, Inc. shares in Q2 2020, an estimated $413K.
GSA Capital Partners first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
GSA Capital Partners's Momenta Pharmaceuticals, Inc. position peaked at $1.58M in Q4 2017.
237 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2020.

Based on GSA Capital Partners's 13F filing for Q2 2020, filed 11 Aug 2020.